PCSK9-IN-11

PCSK9-IN-11

P659182-5mg

5mg

≥99%

2-8°C储存,避光

冰袋运输

PCSK9-IN-11 (compound 5r) is a potent and orally active PCSK9 inhibitor. PCSK9-IN-11 exhibits PCSK9 transcriptional inhibitory activity in HepG2 cells, with an IC 50 of 5.7 μM. PCSK9-IN-11 increases LDL receptor (LDLR) protein level. PCSK9-IN-11 can be us Appearance:Solid IC50& Target:IC50: 5.7 μM (PCSK9) In Vitro:PCSK9-IN-11 (compound 5r) (0-25 μM, 24 h) significantly decreases PCSK9 protein level and increases LDLR expression in a dose dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Bl In Vivo:PCSK9-IN-11 (compound 5r) (0-1000mg/kg, IG, once) exhibits a good in vivo safety feature with the halflethal dose (LD 50 ) value of over 1000mg/kg. PCSK9-IN-11 (30mg/kg, IG, once a day for 8 weeks) significantly suppresses hepatic PCSK9 expression Biological Activity:PCSK9-IN-11 (compound 5r) is a potent and orally active PCSK9 inhibitor. PCSK9-IN-11 exhibits PCSK9 transcriptional inhibitory activity in HepG2 cells, with an IC 50 of 5.7 μM. PCSK9-IN-11 increases LDL receptor (LDLR) protein level. PCSK9-IN-11 can be us

C16H17ClFN5O3

381.79 g/mol

O=C(N1C)N(C)C2=C(N(CC3=CC=CC(Cl)=C3F)C(NCCO)=N2)C1=O

DMSO : 125 mg/mL (327.41 mM; Need ultrasonic)